Skip to content

Your must-see guide to RSNA 2025

Explore
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
featured-image

Press Release

RapidAI Announces $25 Million in Series B Funding

Funding Will be Used to Expand AI-Enhanced Cerebrovascular Imaging Worldwide San Mateo, Calif. — September 17, 2020 – RapidAI, the worldwide leader in advanced imaging for stroke, today announced a $25 million Series B round of funding by Lennertz & Co. Building on years of profitability, these additional funds will accelerate the company’s strategic growth initiatives around the world. Founded in 2011, RapidAI makes the most-widely used advanced cerebrovascular imaging products for patient care, research, and clinical trials. This funding will support the continued advancement of the Rapid ® platform and world-class clinical products. RapidAI clinical products help save lives, RapidAI workflow and messaging technologies help stroke teams save time, and RapidAI analytics and business intelligence products help stroke networks reduce costs and improve patient outcomes. “For several years, we have worked to develop and bring to market the next generation of AI-enhanced cerebrovascular imaging products. We have been rewarded for that dedication with sustained growth and uninterrupted profitability since going to market,” said Don Listwin, CEO of RapidAI. “In the last year, we have expanded our scope from ischemic stroke to hemorrhagic stroke, and with the recent acquisition of EndoVantage, we now address aneurysm. In these difficult global times, t his investment is a significant sign of support, that while others are shrinking and shuttering, we are investing and growing to help build efficient stroke networks across multi-site systems and referral networks.” RapidAI offers an end-to-end portfolio of advanced stroke imaging and stroke assessment products for hospitals of all sizes. The Rapid platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans, helping hospitals to speed up time-critical triage or transfer decisions and facilitate better patient outcomes. “We want our investment monies directed toward companies and teams that demonstrate global vision and a track record of success,” said Philipp Lennertz, Managing Director of Lennertz & Co. "RapidAI’s vision to massively improve stroke and other cerebrovascular care through AI, and other medical imaging innovations, has known no borders and brought measurable improvement to patient care worldwide. We are excited to help them continue and expand on their mission.” “Since RapidAI cofounders, Dr. Albers and Dr. Bammer, presented research that dramatically grew stroke treatment guidelines globally, thousands of other clinicians and I have been able to address more patients and achieve better outcomes,” said Dr. Olav Jansen, Professor at the Department of Radiology and Neuroradiology, UKSH Campus Kiel, Kiel, Germany. “With the Rapid platform’s wide array of AI-enhanced imaging technologies, we have seen opportunities for effective care grow daily.” About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com .
featured-image

Press Release

RapidAI Launches Rapid Web App and Receives ISO 27001 Certification

The ISO 27001 Certification Signifies High Level of Data Security and Management San Mateo, Calif. — September 10, 2020 – RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of the Rapid Web App as well as ISO 27001 data security and management certification. The addition of the Rapid Web App delivers another way for stroke teams to conveniently preview and interact with Rapid ® results and communicate securely. In parallel RapidAI’s ISO 27001 certification acknowledges the company’s significant security and privacy protection protocols. The new Rapid Web App extends access into yet another user environment, offering stroke team members a convenient way to view real-time browser notifications of new cases, preview Rapid results and source files, and enable workflow communications via a desktop or laptop. The app works with Google Chrome and Microsoft Edge browsers to give users an easy way to view, organize, and track cases from multiple sites in one location. “It takes a whole team to treat stroke and we want to ensure our tools meet the team where they are – whether on a phone, desktop, or a laptop,” said Rachel Witalec, Vice President of Product at RapidAI. “With the Rapid Web App team members now have even more ways to ensure they can collaborate and preview time-sensitive stroke imaging across their workflow.” With the Rapid Web App Stay updated: The Rapid Web App delivers new case information to physicians through browser notifications. It saves precious time by giving users the option to preview Rapid results and compressed patient images directly from a desktop or laptop. Faster treatment decisions: The powerful Rapid clinical backend delivers processed imaging results based on NCCT, CTP, CTA and MRI (diffusion and perfusion) scans to the Rapid Web App in minutes. The app helps facilitate faster treatment decisions by giving physicians the ability to immediately preview Rapid results and source files through the built-in Image viewer. Streamlining patient care: The Rapid Web App’s collaboration features facilitate and accelerate acute care coordination. Stroke team members can communicate within the app—centralizing case information, communicating team activation, limiting touchpoints, and reducing miscommunications. Secure, Compliant Access & Communications: The Rapid Web App is integrated with third-party identity providers such as Microsoft Active Directory to support single sign-on and easier activation and deactivation of Rapid Web App accounts. The secure, GDPR and HIPAA-compliant Rapid Web App provides the tools hospitals need to support stroke-care operations. Data security & compliance with ISO 27001 Building on RapidAI’s commitment to secure and compliant data management, today the company also announced it has received ISO 27001 certification, a rigorous information security standard that demonstrates RapidAI’s investment in the people, processes, and technology to protect its platform and data. In addition to a National Institute of Standards and Technology (NIST) cybersecurity framework, RapidAI is HIPAA compliant, GDPR compliant, ISO 13485 and ISO 27001 certified. RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day. For more information, visit RapidAI.com .
featured-image

Press Release

RapidAI Receives FDA Clearance of Rapid LVO

For Identification of Suspected Large Vessel Occlusions Menlo Park, Calif. — August 13, 2020 –RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid LVO has received Food and Drug Administration (FDA) clearance for detecting suspected LVOs (Large Vessel Occlusions). Rapid LVO helps physicians speed up triage or transfer decision-making. Working in as few as 3 minutes, Rapid LVO uses a vessel tracker in conjunction with assessment of brain regions with reduced blood vessel density to identify suspected LVOs with a sensitivity of 97% and a specificity of 96%. Stroke team members are also immediately notified when a suspected LVO is detected. “LVOs are the most disabling and deadly ischemic strokes,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “The ability to identify LVOs rapidly facilitates more effective treatment. This is why we are very excited about the FDA clearance of Rapid LVO, a significant step forward in stroke diagnostics and care.” RapidAI makes the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. Rapid ® is the only clinically validated platform available and considered by many to be the gold standard for advanced cerebrovascular imaging. To learn more visit www.RapidAI.com/Rapid-CTA . About RapidAI RapidAI is the worldwide leader in advanced imaging for stroke. Based on intelligence gained over 1,000,000 scans from more than 1,600 hospitals in over 50 countries, the Rapid ® platform uses artificial intelligence to create high quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The Rapid imaging platform includes Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid LVO, Rapid CTP, and Rapid MRI. RapidAI also offers SurgicalPreview ® , a comprehensive aneurysm management platform. RapidAI empowers clinicians to make faster, more accurate diagnostic and treatment decisions for stroke and aneurysm patients using clinically-proven, data-driven technology. With our validated, trusted products developed by medical experts, clinicians worldwide are improving patient care and outcomes every day.
featured-image

Press Release

RapidAI Celebrates One-Millionth Scan

Thomas Jefferson University Hospital Recognized for One-Millionth Recorded Rapid® Scan Menlo Park, Calif. — July 28, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Thomas Jefferson University Hospital in Philadelphia was the site of the one-millionth recorded Rapid ® scan. Building on its leadership in AI-powered stroke imaging, with this news RapidAI fortifies its standing as the most widely used, clinically validated stroke imaging software for patient care, research, and clinical trials. Based on intelligence gained from an unmatched 1,000,000+ scans from more than 1,600 hospitals in over 50 countries, the artificial intelligence-based Rapid platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI. Now, with over one million scans, RapidAI can leverage even more statistical power and data to enhance performance and improve patient care at individual hospitals as well as larger networks and systems around the world. With its region-wide reputation for quality stroke care, Thomas Jefferson University Hospital in Philadelphia, Pennsylvania, has been awarded the distinction of the one-millionth recorded Rapid scan. “Stroke imaging and care have evolved quickly over the last couple of years, thanks in large part to innovations from the likes of RapidAI as well as expanded AHA/ASA stroke guidelines,” said Pascal Jabbour, MD, Professor of Neurological Surgery and the Chief of the Division of Neurovascular and Endovascular Neurosurgery in the Department of Neurological Surgery at the Sidney Kimmel Medical College at Thomas Jefferson University. “We are gratified to be the site of the one-millionth Rapid scan as we are always in pursuit of the tools, techniques and intelligence that lead to better patient outcomes.” The complete Rapid platform currently includes: Rapid ICH: automatically triages non-contrast CT scans to quickly identify brain Rapid ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury Rapid CTA: automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs) Rapid CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time Rapid MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival Rapid Mobile App: securely preview RapidAI results from multiple sites, receive notifications, and communicate about patient care, anytime, anywhere "It is with great excitement that we honor Thomas Jefferson University Hospital for the one millionth recorded Rapid scan. In parallel, this builds on the over 1,600 hospitals in the U.S. and around the world that rely on RapidAI technology as an integral part of their stroke care every day,” said Don Listwin, CEO of RapidAI. “Also, with the aggregate data of over one million scans, along with predictive algorithms and our RapidAI Insights analytics solution, we can help benchmark data, performance and clinical workflow for single hospital sites and whole networks, improving everyone’s stroke IQ.”
featured-image

Press Release

Leader in Stroke Imaging Introduces RapidAI Insights

New Analytics Platform Delivers Hospitals A Comprehensive View Into Their Stroke Imaging, Patient Care and Business Menlo Park, Calif. — June 16, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of RapidAI Insights. A unique new analytics platform, RapidAI Insights presents Rapid® scan, treatment, and outcomes data to help hospitals and systems make more-informed business decisions, reduce costs across sites, while simultaneously improving patient outcomes, and saving more lives. RapidAI Insights offers a portfolio of analytic reports and is a valuable solution for multi-site systems and referral networks looking to standardize stroke care processes and optimize operational efficiencies. RapidAI Insights Optimizes operational efficiency and effectiveness: RapidAI Insights provides multi-site systems with the intelligence to help monitor the adoption of Rapid products and evaluate return-on-investment (ROI) across sites. Improves processes for emergent stroke care: By combining operational, clinical, and imaging data, RapidAI Insights offers customized reports to deliver deep insights on patient care decisions, treatment effectiveness, and platform usage quality in helping to quickly diagnose and treat stroke patients leading to faster intervention and improved patient outcomes. Increases usage and improves scan protocols: RapidAI Insights enables hospitals to monitor the usage of the Rapid platform by site and proactively ensure proper and consistent use of Rapid products across sites. Enables easier data monitoring and security: RapidAI Insights gives hospital IT and security team members peace of mind on who has access to and is using Rapid products. “At RapidAI we focus on helping hospitals save lives, save time and save money," said Don Listwin, CEO of RapidAI. “Developed with intelligence from over 1,500 sites already using Rapid, RapidAI Insights utilizes the massive amount of critical site and system-wide stroke imaging data to deliver hospitals a best-in-class analytic tool that informs their patient care, as well as the economics of their stroke care business. RapidAI Insights addresses the needs of clinicians, IT departments, and hospital administrators." RapidAI Insights Reports Include Rapid Stats and Usage Insights: A suite of reports that offer data on Rapid utilization, scan details and demographics, and scan quality. Executive Insights: An executive-level report that offers an information-rich summary of site-specific information across systems for those looking to optimize operational efficiencies and reduce costs. Security and Monitoring Insights: Designed to help hospitals support best practices in security, monitoring and compliance auditing; the Security and Monitoring Insights provide IT teams with information on Rapid Mobile App access and usage. Patient Journey and Clinical Outcomes Insights: A customized report that delivers hospitals a detailed view into the patient journey and clinical outcomes to help drive stroke protocol improvements. "As an Interventional Neuroradiologist for a large system, I understand the tremendous value in seeing stroke imaging metrics across patients and our dozens of hospitals in multiple states," said Daniel P. Gibson, MD, and Director, Neurointerventional Surgery. "Analytics coming out of RapidAI Insights help us better understand the opportunities and challenges, which greatly benefit our patients, from the timeliness of care to informing how we handle transfer decisions. In parallel, it also helps our administrators better understand our work from a business perspective."
featured-image

Press Release

Rapid ASPECTS First Neuroimaging Solution with CADx FDA Clearance

AI-Powered Stroke Imaging Solution First to Receive FDA Advanced CADx Clearance to Raise Reading Capabilities for Non-Expert Readers Menlo Park, Calif. — June 16, 2020 —RapidAI, the worldwide leader in advanced imaging for stroke, today announced that Rapid ASPECTS has received Food and Drug Administration (FDA) clearance as the first neuroimaging analysis device in the CADx (Computer-Assisted Diagnostic software) category. Rapid ASPECTS is the only neuroimaging product shown to improve physicians’ interpretations of Non-Contrast CT (NCCT) scans using a standardized ASPECT score. Validated through the rigorous FDA process, the use of Rapid ASPECTS automated score combined with the physician’s review of the scan, improves the accuracy of the ASPECT score calculation which is particularly important for less experienced readers. Based on the Alberta Stroke Program Early CT Scoring (ASPECTS) system, Rapid ASPECTS uses a validated machine-learning algorithm to automatically identify the ASPECTS regions of the brain and generate an ASPECT score to indicate early signs of brain infarction on NCCT scans—helping physicians identify areas of irreversible brain injury. By automating and standardizing this process, Rapid ASPECTS helps stroke teams across hospital sites and referral networks quickly assess patient eligibility for thrombectomy—enabling faster triage and transfer decisions that facilitate better patient outcomes. “Rapid ASPECTS represents the next AI-powered step forward in stroke imaging, and the groundbreaking CADx clearance from the FDA puts it in a class by itself,” said Dr. Greg Albers, Professor of Neurology at Stanford University, Director of the Stanford Stroke Center and cofounder of RapidAI. “In addition to helping stroke teams with faster triage and transfer decisions, Rapid ASPECTS also improves the accuracy of typical readers.” Rapid ASPECTS Provides: Standardized, predictive assessment: In a few minutes, Rapid ASPECTS automatically delivers a standardized ASPECT score—assisting physicians to quickly identify areas of irreversible injury and help determine a patient’s eligibility for thrombectomy. Validated Machine-Learning Intelligence: Rapid ASPECTS delivers fast measurements utilizing a sophisticated, machine-learning algorithm that has been validated in clinical research studies. Faster Triage or Transfer Decisions: Rapid ASPECTS supports collaboration between hospitals and specialists to make faster triage and transfer decisions for patients—helping to facilitate better patient care and outcomes. “The FDA’s advanced CADx clearance has never been granted to a neuroimaging solution before,” said Jim Rosa, Senior Vice President of Regulatory and Clinical at RapidAI. “Through a combination of clinically validated advances in AI and machine learning, Rapid ASPECTS offers a glimpse into the future of stroke imaging.” RapidAI is the most-widely used stroke imaging software for patient care, research, and clinical trials—helping hospitals around the world save time, money, and lives. It is the only clinically validated platform available and the gold standard for advanced cerebrovascular imaging. Based on intelligence gained from over 650,000+ scans from more than 1,500 hospitals in over 50 countries, the artificial intelligence-based Rapid ® platform creates high-quality, advanced images from non-contrast CT, CT angiography, CT perfusion, and MRI diffusion and perfusion scans. The platform offers an end-to-end portfolio of advanced cerebrovascular imaging analysis products—including Rapid ICH, Rapid ASPECTS, Rapid CTA, Rapid CTP, and Rapid MRI. Already in use internationally, Rapid ASPECTS will be commercially available in the U.S. later this month. To learn more, visit rapidai.com/rapid-aspects.
featured-image

Press Release

The Innovator in AI Enhanced Stroke Imaging Officially Becomes RapidAI

RapidAI acquires comprehensive aneurysm management innovator and expands scope to include aneurysm, extending its leadership in cerebrovascular imaging Menlo Park, Calif. — June 9, 2020 — RapidAI, the worldwide leader in advanced imaging for stroke, today announced the acquisition of EndoVantage, developer of the Find, Track and Treat™ comprehensive cerebral aneurysm management platform. A major neurological condition, it is estimated that 1 in 50 people in the U.S. has an unruptured cerebral aneurysm, with one rupturing and resulting in a brain hemorrhage every 18 minutes. With this news, RapidAI continues to expand its scope, from ischemic stroke to hemorrhagic stroke and now aneurysm. In 2019, RapidAI introduced Rapid ICH, the next step in AI-powered imaging technology for hemorrhages. Now with the acquisition of EndoVantage, the company will also add a concentration on aneurysm. Started at Mayo Clinic and Arizona State University, EndoVantage has developed a powerful award-winning computational platform that provides comprehensive cerebral aneurysm management, automating the entire workflow from initial assessment, growth monitoring, to treatment planning. It utilizes CTA and MRA scans to deliver results that help physicians find and track aneurysm progression, and leverages data from 3D rotational angiograms to deliver detailed 3D models of a patient’s vasculature and allow presurgical planning for the repair of the aneurysm. “By adding the incredible technology developed by EndoVantage to the Rapid platform, we strengthen our position as the global leader in cerebrovascular imaging,” said Don Listwin, CEO of RapidAI. “We can offer hospitals a complete portfolio of products—encompassing ischemic stroke, hemorrhagic stroke, and aneurysm—providing an end-to-end solution that will drive better patient outcomes across the spectrum of cerebrovascular disorders.” “We are very excited to join the Rapid platform of technology. EndoVantage covers the spectrum of cerebral aneurysm care from diagnosis through treatment, which helps physicians decide how best to treat their patients,” said Brian Chong MD, cofounder, EndoVantage. "Each patient’s aneurysm is unique, like the patient. Our technology augments a physician’s clinical acumen and experience helping them determine the best plan for each patient.” The complete Rapid® platform currently includes: Rapid ICH : automatically triages non-contrast CT scans to quickly identify brain hemorrhages with a sensitivity of 95% and specificity 94%* Rapid ASPECTS **: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury Rapid CTA : automatically assesses regions of reduced blood flow to identify, locate, and alert stroke teams to the presence of large vessel occlusions (LVOs)**. Rapid CTP : fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time Rapid MRI : fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival Rapid Mobile App : securely view Rapid results from multiple sites with customizable notifications on mobile devices *Excluding hemorrhagic transformations (HTs). **Rapid ASPECTS and LVO detection and localization are not commercially available in the U.S.
featured-image

Press Release

RapidAI Introduces Technology Partner Program to Bring RapidAI Technology to more Hospital Environments

Leading Medical Technology and Communications Companies Join the RapidAI Technology Partner Program Menlo Park, Calif. —February 18, 2020 –RapidAI, the worldwide leader in advanced imaging for stroke, today announced the launch of the RapidAI Technology Partner Program, an ecosystem of technologies that complement or integrate with the Rapid platform. In tandem, the company also released a new RapidAI API (Application Programming Interface) to enable technology partners to integrate Rapid results into their products and services. As part of the mission to deliver the benefits of its products to more patients globally and meet each customer’s unique requirements, RapidAI now partners with companies to bring RapidAI technology to more hospital environments through the RapidAI Technology Partner Program. The program is designed to ensure product compatibility and provide a path for healthcare solution providers to integrate and deliver advanced Rapid results through their products. The RapidAI Technology Partner Program broadens the availability of RapidAI technology in more settings, including Mobile Stroke Units (MSUs) and the Angio Suite. It also expands access to Rapid results through more healthcare communication platforms, and increases the options for deployment and implementation of the Rapid platform—on premise or in the cloud. Today, RapidAI is also launching the RapidAI API, which is designed to integrate Rapid notifications and results into a portfolio of workflow and medical communication applications used by healthcare providers to coordinate stroke care for optimal patient outcomes. The RapidAI Technology Partner Program members include Allm, Ambra Health, Halo Communications, Mobile Heartbeat, Pulsara, Samsung Neurologica, Siemens Healthineers, Spok, and TigerConnect. “It is great to see so many leaders in medical technology, workflow, and communications commit to bringing RapidAI technology to more hospital environments and help stroke teams achieve better patient outcomes.” said Don Listwin, CEO of RapidAI. “Every hospital is unique, and in a commitment to delivering Rapid their way, this is yet another path to provide more customer choice.” Partner Quotes “RapidAI’s technology and Allm’s Join app based communications have become a critical and integrated part of stroke care in the U.S. and around the world. Through the RapidAI Technology Partner Program we are helping improve access to life-saving information and results while also speeding the time to care through better communication.” -- Harry Reddy, President of Allm North America We are thrilled to be a RapidAI technology partner. We believe that our solutions partnered together can offer clinicians the resources they need to make critical decisions when time is of the essence." -- Andrew Duckworth, VP of Business Development, Ambra Health “Halo is excited to partner with RapidAI. Halo, together with the Rapid advanced cerebrovascular imaging platform, will help ensure accurate and time-sensitive patient information is communicated to appropriate clinicians. When it comes to treating stroke victims, time is of the essence, and between Halo’s robust clinical communication platform and the RapidAI technology the right teams and individuals can be quickly mobilized to produce better patient outcomes.” -- Angel Mena, M.D., Chief Medical Officer, Halo Communications “We are excited to partner with RapidAI and integrate their advanced neuroimaging platform into the MH-CURE platform via our CURE Connect APIs and the RapidAI API. By leveraging our respective technologies, we can provide a powerful tool to our mutual customers in their drive to save patients afflicted with stroke.” -- Mike Detjen, COO at Mobile Heartbeat “AI is quickly becoming an integral part of all medical imaging offerings. Here at NeuroLogica our mission is to provide more than just imaging equipment, it's to provide health care solutions. Partnerships with companies like RapidAI are essential in accomplishing that mission.” -- David Webster, COO at Neurologica “Siemens Healthineers is proud to work together with RapidAI on exciting new innovations in stroke imaging and care. We embrace the power of this partnership to support our One Stop Stroke initiative.” -- Philip Stenner, Global Head of Marketing Interventional Radiology, Siemens Healthineers “Spok is pleased to be a part of the RapidAI Technology Partner Program. Through our partnership with RapidAI, Spok Go® will automate the delivery of critical stroke results, activating the responsible care team across the hospital network. Together, RapidAI and Spok Go will enable care teams in the 2,200+ hospitals that Spok serves to receive critical results on their preferred devices, improving care team collaboration, expediting time to treatment, and helping drive better patient outcomes.” -- Dave Nuthals, VP Product Strategy, Spok
featured-image

Press Release

Press Release: The Innovator in AI Enhanced Stroke Imaging Officially Becomes RapidAI

The company that pioneered the usage of artificial intelligence (AI) in advanced imaging for stroke, embraces AI leadership with a new brand. Menlo Park, Calif. —February 18, 2020 – iSchemaView, also known as RAPID, the worldwide leader in advanced imaging for stroke, today announced the company is now RapidAI. In 2018, co-founder Dr. Greg Albers presented groundbreaking findings at the International Stroke Conference (ISC) that supported expanded treatment window guidelines for stroke patients. Based on intelligence gained from over 650,000 scans across more than 1,500 hospitals in over 50 countries, the AI-enhanced Rapid platform has become the gold standard for advanced imaging for stroke. Now on the heels of unprecedented worldwide usage and availability of the Rapid platform, RapidAI is unveiling new branding, a new website, and technology partner news at ISC 2020 (Booth #315). RapidAI News from ISC 2020 at the Los Angeles Convention Center, Feb 18-21 RAPID becomes RapidAI. The company that leads AI-enhanced stroke imaging around the globe, embraces the future with a new brand and website, RapidAI.com . RapidAI Launches Technology Partner Program. The RapidAI Technology Partner Program gives customers the flexibility to deploy the Rapid platform and access Rapid results according to their organization’s needs. The program broadens the availability of RapidAI technology in more environments, including Mobile Stroke Units (MSUs) and Angio Suites. It also expands access to RapidAI results through more healthcare communication platforms, and increases the options for deployment and implementation of the Rapid platform—on premise or in the cloud. RapidAI Product Showcase Highlights at ISC The full Rapid advanced imaging platform which includes Rapid CTP, Rapid MRI, Rapid CTA, Rapid ICH, and Rapid ASPECTS The Rapid Mobile App provides stroke team members fast access to RapidAI results, the ability to preview source files, and communicate about patient care Rapid U, the advanced role-based training and certification program for Rapid products The RapidAI Presentation Theater at the International Stroke Conference 2020 Stop by the RapidAI booth #315. Grab a seat and learn about the latest advancements in comprehensive stroke care from Dr. Greg Albers and other leaders in stroke. The full schedule of sessions can be found at https://www.rapidai.com/isc2020presentationtheater and include: Precision Medicine and the Future of Stroke Care Mobile Stroke Units: Conclusive Field Diagnosis and Improved Patient Routing Case Study: Suffolk County's Mobile Stroke Units Optimizing Workflows for Hyper-Acute Stroke Patients Mobilizing Clinical Communications at Enterprise Scale Case study: Coordinating and Streamlining Acute Stroke Care Communication To learn more visit RapidAI at booth #315, and online at RapidAI.com
4 5 6 7 8